HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions

The Pharmacogenomics Journal
Sijia YanQing-he Xing

Abstract

Xuesaitong (XST) is mainly used to treat cardiovascular and cerebrovascular diseases, sometimes causing cutaneous adverse drug reactions (cADRs) with unknown mechanisms of pathogenicity or risk factors. We aimed to verify whether human leukocyte antigen (HLA) alleles are associated with XST-related cADRs in Han Chinese population. We carried out an association study including 12 subjects with XST-induced cADRs, 283 controls, and 28 XST-tolerant subjects. Five out of 12 patients with XST-induced cADRs carried HLA-C*12:02, and all of them received XST via intravenous drip. The carrier frequency of HLA-C*12:02 was significantly high compare to that of the control population (Pc = 4.4 × 10-4, odds ratio (OR) = 21.75, 95% CI = 5.78-81.88). Compared with that of the XST-tolerant group, the patients who received XST through intravenous drip presented a higher OR of cADRs (Pc = 0.011, OR = 27.00, 95% CI = 2.58-282.98). The results suggest that HLA-C*12:02 is a potentially predictive marker of XST-induced cADRs in Han Chinese, especially when XST is administered via intravenous drip.

References

Aug 1, 1991·Journal of Clinical Pharmacy and Therapeutics·N P Murray, M J Daly
Dec 11, 1999·Nucleic Acids Research·H M BermanP E Bourne
Jun 26, 2003·Nucleic Acids Research·Torsten SchwedeManuel C Peitsch
May 1, 1956·Annals of Human Genetics·J B HALDANE
Sep 10, 2005·Chinese Journal of Integrative Medicine·Shang-qian ZhongYin-yuan Zhong
Feb 24, 2006·Planta medica·Yong LiuLing Yang
Mar 21, 2006·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yong LiuLing Yang
Jun 22, 2007·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S J Posadas, W J Pichler
Feb 8, 2008·The New England Journal of Medicine·Simon MallalUNKNOWN PREDICT-1 Study Team
Feb 28, 2008·The Pharmacogenomics Journal·M R NelsonM G Ehm
Jun 26, 2008·The British Journal of Ophthalmology·M UetaS Kinoshita
Dec 19, 2009·Handbook of Experimental Pharmacology·Munir Pirmohamed
Feb 2, 2010·Trends in Pharmacological Sciences·Tamara J NicolsonRuth R A Roberts
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
Mar 23, 2011·Journal of Computational Chemistry·Samir UnniNathan A Baker
Mar 25, 2011·The New England Journal of Medicine·Pei ChenUNKNOWN Taiwan SJS Consortium
Oct 25, 2011·Annual Review of Pharmacology and Toxicology·Mandvi BharadwajJames McCluskey
Dec 8, 2011·Annals of Dermatology·Young-Min SonJoo-Young Roh
Nov 13, 2012·Current Opinion in Immunology·Patricia T IllingJames McCluskey
Mar 7, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·A BarbaudI Aimone-Gastin
Jun 15, 2013·The Journal of Dermatological Treatment·Giuseppe PistoneMaria Rita Bongiorno
Jul 11, 2013·Planta medica·Zheng XiangHaixue Kuang
Oct 25, 2013·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·J YunD Yerly
Aug 8, 2014·The Journal of Dermatology·Tomotaka MabuchiAkira Oka
Apr 19, 2015·BMC Complementary and Alternative Medicine·Xiaomeng ZhangBing Zhang
Jun 27, 2017·Nature Communications·Gurman KaurLars Fugger

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

R
MODEL SERVER
Crystallographic Object - Oriented Toolkit
APBS
SWISS
PDB2PQR
PyMOL

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.